Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) is set to announce its earnings results after the market closes on Tuesday, November 7th. Analysts expect the company to announce earnings of $2.53 per share for the quarter. Jazz Pharmaceuticals PLC has set its FY17 guidance at $10.70-11.30 EPS.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last issued its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.85 by ($0.13). The business had revenue of $394.39 million for the quarter, compared to analyst estimates of $410.83 million. Jazz Pharmaceuticals PLC had a return on equity of 22.75% and a net margin of 25.69%. The firm’s revenue for the quarter was up 3.5% on a year-over-year basis. During the same period last year, the company posted $2.67 earnings per share. On average, analysts expect Jazz Pharmaceuticals PLC to post $10 EPS for the current fiscal year and $11 EPS for the next fiscal year.

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) traded up $0.04 during trading hours on Monday, hitting $137.93. 3,803 shares of the company’s stock were exchanged, compared to its average volume of 446,163. The firm has a market capitalization of $8,285.94, a PE ratio of 19.15, a price-to-earnings-growth ratio of 0.83 and a beta of 1.00. Jazz Pharmaceuticals PLC has a 52 week low of $95.80 and a 52 week high of $163.75. The company has a quick ratio of 2.49, a current ratio of 2.65 and a debt-to-equity ratio of 0.74.

A number of analysts recently weighed in on JAZZ shares. Deutsche Bank AG set a $175.00 price objective on shares of Jazz Pharmaceuticals PLC and gave the stock a “buy” rating in a report on Wednesday, August 9th. Royal Bank Of Canada reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals PLC in a report on Wednesday, August 9th. Janney Montgomery Scott reaffirmed a “buy” rating and issued a $192.00 price objective (up previously from $180.00) on shares of Jazz Pharmaceuticals PLC in a report on Wednesday, August 9th. Zacks Investment Research raised shares of Jazz Pharmaceuticals PLC from a “hold” rating to a “buy” rating and set a $174.00 price objective on the stock in a report on Tuesday, August 8th. Finally, Cowen and Company set a $190.00 target price on shares of Jazz Pharmaceuticals PLC and gave the company a “buy” rating in a research report on Monday, August 21st. One analyst has rated the stock with a sell rating, six have assigned a hold rating and eighteen have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $180.88.

In other news, EVP Michael Patrick Miller sold 200 shares of the firm’s stock in a transaction on Tuesday, August 15th. The shares were sold at an average price of $144.38, for a total value of $28,876.00. Following the sale, the executive vice president now owns 21,996 shares in the company, valued at $3,175,782.48. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Bruce C. Cozadd sold 1,000 shares of the firm’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $150.00, for a total transaction of $150,000.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 4,517 shares of company stock worth $665,623. 4.30% of the stock is currently owned by corporate insiders.

WARNING: “Jazz Pharmaceuticals PLC (JAZZ) to Release Quarterly Earnings on Tuesday” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/11/06/jazz-pharmaceuticals-plc-jazz-to-release-quarterly-earnings-on-tuesday.html.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Earnings History for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Stock Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related stocks with our FREE daily email newsletter.